Medtronic increases purchase price for Avecor
This article was originally published in Clinica
Medtronic has stepped up its offer for Avecor Cardiovascular and will pay $13 in shares for each Avecor share rather than its original bid of $11.125. This price matches the offer made by another, unnamed company. Medtronic will also pay Avecor up to $10 million if the Federal Trade Commission (FTC) fails to clear the deal by March 15 1999.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.